BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 16859736)

  • 1. Is complete surgical staging necessary in patients with stage I mucinous epithelial ovarian tumors?
    Cho YH; Kim DY; Kim JH; Kim YM; Kim KR; Kim YT; Nam JH
    Gynecol Oncol; 2006 Dec; 103(3):878-82. PubMed ID: 16859736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is it justified to classify patients to Stage IIIC epithelial ovarian cancer based on nodal involvement only?
    Cliby WA; Aletti GD; Wilson TO; Podratz KC
    Gynecol Oncol; 2006 Dec; 103(3):797-801. PubMed ID: 17052746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
    Silva EG; Gershenson DM; Malpica A; Deavers M
    Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical staging of ovarian low malignant potential tumors.
    Rao GG; Skinner E; Gehrig PA; Duska LR; Coleman RL; Schorge JO
    Obstet Gynecol; 2004 Aug; 104(2):261-6. PubMed ID: 15291997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The benefits of low anterior en bloc resection as part of cytoreductive surgery for advanced primary and recurrent epithelial ovarian cancer patients outweigh morbidity concerns.
    Park JY; Seo SS; Kang S; Lee KB; Lim SY; Choi HS; Park SY
    Gynecol Oncol; 2006 Dec; 103(3):977-84. PubMed ID: 16837030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical and pathological features of borderline ovarian tumors].
    Li Y; Cui H; Shen DH; Zhao Y; Wei LH; Qian HN
    Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):81-4. PubMed ID: 12783693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The clinical significance of retroperitoneal lymph node metastasis and lymphadenectomy on 3-year survival in ovarian carcinoma].
    Takahashi Y; Akiyama M; Hirose M; Yamamoto Y; Tenzaki T; Ishiguro T; Noda Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1993 Oct; 45(10):1095-100. PubMed ID: 8245587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical behavior of serous and mucinous borderline tumors of the ovary with diploid DNA stem line. Follow-up studies after organ preserving and non-organ preserving therapy].
    Mecke H; Börner-Klaussner B; Grosse G; Nadjari B; Hauptmann S
    Zentralbl Gynakol; 2000; 122(5):274-9. PubMed ID: 10857214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recurrence risk factors of platinum-sensitive epithelial ovarian cancer].
    Yan XJ; Liang LZ; Zeng ZY; Liu JH; Yuan SH; Wei M
    Ai Zheng; 2005 Jun; 24(6):751-4. PubMed ID: 15946495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of ovarian cancer patients who underwent incomplete surgical staging.
    Panprom P; Lertkhachonsuk R
    J Med Assoc Thai; 2008 Sep; 91(9):1323-30. PubMed ID: 18843859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinicopathologic features of 234 cases with borderline ovarian tumors].
    Ren J; Lou JY; Liu H; Wang P; Zhang JW; Yang KX; Wang HJ; Qie MR; Peng ZL
    Zhonghua Fu Chan Ke Za Zhi; 2009 Feb; 44(2):116-20. PubMed ID: 19570422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of appendectomy at the time of primary surgery in patients with early-stage ovarian cancer.
    Ramirez PT; Slomovitz BM; McQuinn L; Levenback C; Coleman RL
    Gynecol Oncol; 2006 Dec; 103(3):888-90. PubMed ID: 16806436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis.
    Sherman ME; Mink PJ; Curtis R; Cote TR; Brooks S; Hartge P; Devesa S
    Cancer; 2004 Mar; 100(5):1045-52. PubMed ID: 14983501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of therapeutic efficacy between TP regimen and CBP regimen on epithelial ovarian cancer after optimal cytoreductive operation].
    Gao KF; Liu FY; Chen FJ; Feng YL
    Ai Zheng; 2007 Apr; 26(4):431-4. PubMed ID: 17430668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrence and prognostic factors in borderline ovarian tumors.
    Ayhan A; Guvendag Guven ES; Guven S; Kucukali T
    Gynecol Oncol; 2005 Sep; 98(3):439-45. PubMed ID: 16009407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian serous borderline tumors with invasive peritoneal implants.
    Gershenson DM; Silva EG; Levy L; Burke TW; Wolf JK; Tornos C
    Cancer; 1998 Mar; 82(6):1096-103. PubMed ID: 9506355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
    Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
    Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
    Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The current status of surgical staging of ovarian serous borderline tumors.
    Lin PS; Gershenson DM; Bevers MW; Lucas KR; Burke TW; Silva EG
    Cancer; 1999 Feb; 85(4):905-11. PubMed ID: 10091769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.